Full-Time

Neuroscientist/Senior Neuroscientist

Autophagy

Confirmed live in the last 24 hours

Retro Biosciences

Retro Biosciences

51-200 employees

Develops therapeutics targeting aging mechanisms

Biotechnology
Healthcare

Compensation Overview

$140k - $190kAnnually

Senior

San Carlos, CA, USA

Position is onsite in Redwood City, CA.

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • A PhD in Neuroscience or a related field and at least five years of post-doctoral or two years of industry experience.
  • Significant experience with in vivo behavioral assessments.
  • Up-to-date knowledge in cell and molecular biology, iPSC culture, neuronal differentiation and culture, autophagy-lysosomal pathway or lysosomal degradation, and confocal imaging.
  • Worked with cellular disease models of neurodegeneration to develop assays for hit validation.
  • Experience independently conducting and interpreting complex biological experiments.
  • A passion for solving the puzzle of neurodegeneration and thereby bettering the lives of millions of people.
Responsibilities
  • Design, lead, and conduct in vivo experiments that include animal models, behavioral testing, and analysis.
  • Utilize advanced neurobiology techniques to investigate and understand mechanisms of neurodegeneration.
  • Evaluate large data sets to refine, inform, and design subsequent experiments.
  • Provide scientific insights and in-depth data interpretation to inform decision-making within the research team and for senior leaders.
  • Serve as a technical expert in resolving technical and workflow issues, drawing conclusions, making recommendations, and working with other departments as necessary to plan and expedite project objectives.
  • Demonstrate initiative, resourcefulness, and attention to detail within a multidisciplinary team of scientists.
  • Stay current with relevant scientific literature and implement new techniques or practices to improve quality and efficiency.

Retro Biosciences focuses on extending healthy human lifespan by developing therapeutics that target the cellular mechanisms of aging. The company works on three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of development. By addressing the root causes of age-related diseases, Retro Biosciences aims to reduce healthcare costs associated with these conditions, which make up a significant portion of U.S. healthcare spending. The company utilizes advanced technologies like single-cell multi-omics and computational biology to support its research. With $180 million in funding, Retro Biosciences is positioned to advance its therapeutic candidates towards clinical applications, aiming to make significant contributions to age-related disease prevention.

Company Stage

Seed

Total Funding

$175.1M

Headquarters

Redwood City, California

Founded

2021

Growth & Insights
Headcount

6 month growth

9%

1 year growth

25%

2 year growth

180%
Simplify Jobs

Simplify's Take

What believers are saying

  • Retro Biosciences' mission to extend healthy human lifespan by ten years offers a compelling and impactful vision for employees.
  • The company's robust pipeline and advanced technologies like single-cell multi-omics and computational biology provide ample opportunities for innovation and career growth.
  • Strong financial backing and high-profile investments, such as from Sam Altman, ensure long-term stability and resources for research and development.

What critics are saying

  • The ambitious goal of extending human lifespan by ten years involves high scientific and regulatory uncertainties.
  • Dependence on successful clinical trials and commercialization of therapeutic candidates poses significant risks.

What makes Retro Biosciences unique

  • Retro Biosciences focuses on extending healthy human lifespan by targeting the cellular mechanisms of aging, a unique approach compared to traditional biotech firms.
  • Their diversified business model, which includes cellular reprogramming, plasma-inspired therapeutics, and autophagy, provides a balanced pipeline of potential treatments.
  • Significant initial funding of $180 million and partnerships like the $85 million deal with Multiply Labs for automated cell therapy manufacturing set Retro Biosciences apart in terms of financial backing and technological advancement.

Help us improve and share your feedback! Did you find this helpful?